The group of Mark L. Day found that ADAM15 transcript and protein levels were significantly increased in breast and prostate cancer tissue specimens and that expression of this molecule correlated with disease progression and metastasis according to clinical parameters of predictive outcome for both prostate and breast cancers, evidenced by Gleason sum and angioinvasion, respectively [168]. Here, ADAM15 is linked to prostate cancer.